Notice of Meeting: Secretary's Advisory Committee on Genetics, Health, and Society, 63718-63719 [E8-25485]
Download as PDF
<![CDATA[
63718
Federal Register / Vol. 73, No. 208 / Monday, October 27, 2008 / Notices
commercialize methods of increasing
epithelial cell growth. Please contact
John D. Hewes, PhD at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Dated: October 20, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–25566 Filed 10–24–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meetings
mstockstill on PROD1PC66 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; K08, K23, K99–NEI
Research Training Applications.
Date: November 14, 2008.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel and Executive
Meeting Center, 8120 Wisconsin Avenue,
Bethesda, MD 20814.
Contact Person: Samuel Rawlings, PhD,
Chief, Scientific Review Branch, Division of
Extramural Research National Eye Institute,
5635 Fishers Lane, Suite 1300, MSC 9300,
Bethesda, MD 20892–9300, 301–451–2020,
rawlings@nei.nih.gov.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Cooperative
Agreement Review.
Date: November 20, 2008.
Time: 3 p.m. to 5:30 p.m.
Agenda: To review and evaluate
cooperative agreement Applications.
Place: National Institutes of Health, 5635
Fishers Lane, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Houmam H Araj, PhD,
Scientific Review Administrator, Division of
Extramural Research, National Eye Institute,
NIH, 5635 Fishers Lane, Suite 1300,
Bethesda, MD 20892–9602, 301–451–2020,
ha50c@nih.gov.
VerDate Aug<31>2005
17:13 Oct 24, 2008
Jkt 217001
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Core Grants for
Vision Research Review.
Date: December 5, 2008.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Houmam H Araj, PhD,
Scientific Review Administrator, Division of
Extramural Research, National Eye Institute,
NIH, 5635 Fishers Lane, Suite 1300,
Bethesda, MD 20892–9602, 301–451–2020,
ha50c@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: October 17, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–25357 Filed 10–24–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Resident Research RFA.
Date: December 8–9, 2008.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Washington, DC, 2401
M Street, NW., Washington, DC 20037.
Contact Person: Raul A Saavedra, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research, NINDS/NIH/DHHS, Nsc; 6001
Executive Blvd., Ste. 3208, Bethesda, MD
20892–9529, 301–496–9223,
saavedrr@ninds.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: October 15, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–25626 Filed 10–24–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Meeting: Secretary’s
Advisory Committee on Genetics,
Health, and Society
Pursuant to Public Law 92–463,
notice is hereby given of the 17th
meeting of the Secretary’s Advisory
Committee on Genetics, Health, and
Society (SACGHS), U.S. Public Health
Service. The meeting will be held from
8 a.m. to approximately 5:30 p.m. on
Monday, December 1, 2008, and 8 a.m.
to approximately 3 p.m. on Tuesday,
December 2, 2008, at the Hubert H.
Humphrey Building, 200 Independence
Avenue, SW., Washington, DC 20201.
The meeting will be open to the public
with attendance limited to space
available. The meeting also will be Web
cast.
For most of the first day of the
meeting, SACGHS will review a
preliminary draft report that addresses
questions about whether gene patents
and certain licensing practices are
affecting patient access to genetic tests.
SACGHS will discuss the draft report
and determine whether it is ready to be
released for public comment. Later in
the day, the Committee will hear
presentations about diagnostic
laboratory standards and technology
platforms and the role they are playing
in innovation of genetic technologies.
On day two, the Committee will
continue to discuss priority issues and
future study topics and come to a final
decision about its strategic study plan.
As always, the Committee welcomes
hearing from anyone wishing to provide
public comment on any issue related to
genetics, health and society. Individuals
who would like to provide public
comment should notify the SACGHS
Executive Secretary, Ms. Sarah Carr, by
telephone at 301–496–9838 or e-mail at
carrs@od.nih.gov. The SACGHS office is
located at 6705 Rockledge Drive, Suite
750, Bethesda, MD 20892. Anyone
planning to attend the meeting who is
in need of special assistance, such as
sign language interpretation or other
E:\FR\FM\27OCN1.SGM
27OCN1
Federal Register / Vol. 73, No. 208 / Monday, October 27, 2008 / Notices
reasonable accommodations, is also
asked to contact the Executive
Secretary.
Under authority of 42 U.S.C. 217a,
Section 222 of the Public Health Service
Act, as amended, the Department of
Health and Human Services established
SACGHS to serve as a public forum for
deliberations on the broad range of
human health and societal issues raised
by the development and use of genetic
and genomic technologies and, as
warranted, to provide advice on these
issues. The draft meeting agenda and
other information about SACGHS,
including information about access to
the Web cast, will be available at the
following Web site: https://
www4.od.nih.gov/oba/sacghs.htm.
Dated: October 20, 2008.
Jennifer Spaeth,
Director, NIH Office of Federal Advisory
Committee Policy.
[FR Doc. E8–25485 Filed 10–24–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2006–0073]
National Protection and Programs
Directorate; Notice of Availability of
Risk-Based Performance Standards
Guidance for the Chemical Facility
Anti-Terrorism Standards
National Protection and
Programs Directorate, DHS.
ACTION: Notice of availability; request
for comments.
AGENCY:
SUMMARY: The Department of Homeland
Security (DHS) is accepting comments
on the draft ‘‘Risk-Based Performance
Standards’’ Guidance associated with
the Chemical Facility Anti-Terrorism
Standards.
Comments must be received by
November 26, 2008.
ADDRESSES: Comments must be
identified by docket number DHS–
2006–0073 and may be submitted by
one of the following methods:
• Federal Rulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Dennis Deziel, U.S.
Department of Homeland Security,
National Protection and Programs
Directorate, Office of Infrastructure
Protection, Infrastructure Security
Compliance Division, Mail Stop 8100,
Washington, DC 20528.
FOR FURTHER INFORMATION CONTACT:
Dennis Deziel, Office of Infrastructure
Protection, Mail Stop 8100, Washington,
mstockstill on PROD1PC66 with NOTICES
DATES:
VerDate Aug<31>2005
17:13 Oct 24, 2008
Jkt 217001
DC 20528, telephone number (703) 235–
5263.
SUPPLEMENTARY INFORMATION:
I. Public Participation
DHS invites interested persons to
contribute suggestions and comments
on the draft document entitled ‘‘RiskBased Performance Standards
Guidance’’ (RBPS Guidance) by
submitting written data, views, or
arguments. Comments that will provide
the most assistance to DHS will explain
the reason for any recommended
changes to the RBPS Guidance and
include data, information, or authority
that supports such recommended
changes. DHS requests that commenters
identify the proposed changes by page
and line number, and/or by Figure or
Table number. The RBPS Guidance can
be viewed or downloaded at https://
www.dhs.gov/chemicalsecurity and
https://www.regulations.gov.
Instructions: All submissions received
must include the agency name and
docket number for this action. All
comments received will be posted
without change to https://
www.regulations.gov, including any
personal information provided. You
may submit your comments and
material by one of the methods specified
in the ADDRESSES section above. Please
submit your comments and any
supporting material by only one means
to avoid the receipt and review of
duplicate submissions. If you submit
comments by mail, your submission
should be an unbound document and no
larger than 8.5 by 11 inches to enable
copying and electronic document
management.
Docket: The RBPS Guidance and any
comments received can be viewed at
https://www.regulations.gov by searching
the docket number referenced above.
II. Background
In Section 550 of the Homeland
Security Appropriations Act of 2007
(Pub. L. 109–295) (Section 550),
Congress gave DHS regulatory authority
over security at high-risk chemical
facilities. Section 550 instructed DHS to
require all high-risk chemical facilities
to complete Security Vulnerability
Assessments (SVAs), develop Site
Security Plans (SSPs), and implement
protective measures necessary to meet
DHS-defined risk-based performance
standards.
Pursuant to its congressional
mandate, DHS promulgated the
Chemical Facility Anti-Terrorism
Standards (CFATS), 6 CFR Part 27, the
interim final regulations setting forth
the requirements that high risk (i.e.,
‘‘covered’’) chemical facilities must
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
63719
meet to comply with the Act. See 72 FR
17688 (Apr. 9, 2007). Among other
things, CFATS establishes eighteen
Risk-Based Performance Standards
(RBPSs), which identify the areas for
which DHS will examine a high-risk
facility’s security posture; they include
perimeter security, access control,
personnel surety, and cyber security.
To meet the RBPSs, covered facilities
may choose whatever security programs
or processes they deem appropriate, so
long as DHS determines that those
measures achieve the requisite level of
performance in each applicable area.
The programs and processes a high-risk
facility ultimately chooses to implement
to meet these standards must be
described in the facility’s SSP or, if the
facility chooses, in an Alternative
Security Program (ASP) that meets the
requirements of Section 550 and
CFATS. It is through a review of the SSP
(or ASP), combined with an on-site
inspection, that DHS will determine
whether or not a high-risk facility has
met the requisite levels of performance
established by the RBPSs, given the
facility’s individual circumstances.
As required by 6 CFR 27.230(a), DHS
has developed the RBPS Guidance to
assist high-risk chemical facilities in
selecting and implementing appropriate
protective measures and practices to
meet the applicable RBPSs. The draft
RBPS Guidance describes the general
level of performance that facilities in
each of the risk-based tiers created by
CFATS should strive to achieve under
each RBPS. It also seeks to help
facilities comply with CFATS by
describing in greater detail the eighteen
RBPSs enumerated in CFATS, and by
providing examples of various security
measures and practices that facilities
could consider to achieve the desired
level of performance for each RBPS at
each tier.
The draft RBPS Guidance reflects
DHS’s current views on certain aspects
of the RBPSs and does not have the
force or effect of law. The specific
security measures and practices
discussed in this document are neither
mandatory nor necessarily the
‘‘preferred solution’’ for complying with
the RBPSs. Rather, they are examples of
measures and practices that a high risk
facility may choose to consider as part
of its overall strategy to address the
RBPSs. High-risk facility owners/
operators have the option to choose and
implement other measures to meet the
RBPSs based on the facility’s
circumstances, including its tier level,
security issues and risks, physical and
operating environments, and other
appropriate factors, so long as DHS
determines that the suite of measures
E:\FR\FM\27OCN1.SGM
27OCN1
]]>Agencies
[Federal Register Volume 73, Number 208 (Monday, October 27, 2008)]
[Notices]
[Pages 63718-63719]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-25485]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Meeting: Secretary's Advisory Committee on Genetics,
Health, and Society
Pursuant to Public Law 92-463, notice is hereby given of the 17th
meeting of the Secretary's Advisory Committee on Genetics, Health, and
Society (SACGHS), U.S. Public Health Service. The meeting will be held
from 8 a.m. to approximately 5:30 p.m. on Monday, December 1, 2008, and
8 a.m. to approximately 3 p.m. on Tuesday, December 2, 2008, at the
Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington,
DC 20201. The meeting will be open to the public with attendance
limited to space available. The meeting also will be Web cast.
For most of the first day of the meeting, SACGHS will review a
preliminary draft report that addresses questions about whether gene
patents and certain licensing practices are affecting patient access to
genetic tests. SACGHS will discuss the draft report and determine
whether it is ready to be released for public comment. Later in the
day, the Committee will hear presentations about diagnostic laboratory
standards and technology platforms and the role they are playing in
innovation of genetic technologies. On day two, the Committee will
continue to discuss priority issues and future study topics and come to
a final decision about its strategic study plan.
As always, the Committee welcomes hearing from anyone wishing to
provide public comment on any issue related to genetics, health and
society. Individuals who would like to provide public comment should
notify the SACGHS Executive Secretary, Ms. Sarah Carr, by telephone at
301-496-9838 or e-mail at carrs@od.nih.gov. The SACGHS office is
located at 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. Anyone
planning to attend the meeting who is in need of special assistance,
such as sign language interpretation or other
[[Page 63719]]
reasonable accommodations, is also asked to contact the Executive
Secretary.
Under authority of 42 U.S.C. 217a, Section 222 of the Public Health
Service Act, as amended, the Department of Health and Human Services
established SACGHS to serve as a public forum for deliberations on the
broad range of human health and societal issues raised by the
development and use of genetic and genomic technologies and, as
warranted, to provide advice on these issues. The draft meeting agenda
and other information about SACGHS, including information about access
to the Web cast, will be available at the following Web site: https://
www4.od.nih.gov/oba/sacghs.htm.
Dated: October 20, 2008.
Jennifer Spaeth,
Director, NIH Office of Federal Advisory Committee Policy.
[FR Doc. E8-25485 Filed 10-24-08; 8:45 am]
BILLING CODE 4140-01-P
